Caricamento...
No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications
Tamoxifen reduces recurrence risk among women treated for estrogen receptor-positive breast cancer. Its effectiveness partly depends on metabolic activation via cytochrome P450 2D6 (CYP2D6). Some medications compromise CYP2D6 activity and may lower plasma concentrations of active tamoxifen metabolit...
Salvato in:
| Autori principali: | , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2009
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2742564/ https://ncbi.nlm.nih.gov/pubmed/19690182 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1055-9965.EPI-09-0516 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|